BioSig Technologies Welcomes Natasha Russkina as Managing Director, Europe
31.5.2017 09:00 | NASDAQ OMX
MINNEAPOLIS, May 31, 2017 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (OTCQB:BSGM), a medical device company developing a proprietary platform designed to address an unmet technology need for the $4+ billion electrophysiology (EP) marketplace, today announced that Ms. Natasha Russkina has joined the Company as Managing Director, Europe.
Natasha Russkina is founder and director of Augeous Consulting in Geneva, Switzerland, a firm that provides various levels of business development capabilities to companies in the life science sector. Ms. Russkina has over 13 years of experience in international business development, including over 9 years at IG Group PLC, a British FTSE 250 company and a global leader in online trading. During this time, she was responsible for the Group's global business development successfully delivering a number of high level projects from opening new international branches to global rebranding, and providing all initial and ongoing business support to 12 international offices in Europe, South Africa and Australia, a business sector, which accounted for 40% of the Group's revenue. During her career, she had been appointed by the Board of Directors to open a new IT development office in Eastern Europe and was responsible for all parts of operations. During this assignment, the office grew from 14 inherited members of staff to over 135.
"I'm very privileged to join BioSig Technologies during this key time of the company's business development," Natasha commented. "BioSig is an innovative company, which has human talent and technological capacities to deliver game-changing systems in modern bioelectric medicine; a company, which believes in serving the global community. Positioning ourselves in Switzerland, the country well-renowned for its outstanding healthcare system, top talent and love for innovation, provides us with a solid base for reaching the second largest EP market in the world."
Kenneth Londoner, Executive Chairman of BioSig Technologies, Inc. commented, "Europe is a large market for our technology platform. Having a presence in Geneva will augment our growth strategy as we look to commercialize the PURE EP System. Natasha is an outstanding business development talent who will advance our capabilities in the region and we look forward to her leadership providing value for our shareholders and future partners."
About BioSig Technologies
BioSig Technologies is a medical device company developing a proprietary technology platform designed to improve the $4 billion electrophysiology (EP) marketplace (www.biosigtech.com). Led by a proven management team and a veteran, independent Board of Directors, Minneapolis-based BioSig Technologies is preparing to commercialize its PURE EP(TM) System. The technology has been developed to address an unmet need in a large and growing market.
The PURE EP System is a novel cardiac signal acquisition and display system which is engineered to assist electrophysiologists in clinical decision making during procedures to diagnose and treat patients with abnormal heart rates and rhythms. BioSig's main goal is to deliver technology to improve upon catheter ablation treatments for the prevalent and deadly arrhythmias, Atrial Fibrillation and Ventricular Tachycardia. BioSig has partnered with Minnetronix on technology development and is working toward FDA 510(k) clearance and CE Mark for the PURE EP System.
BioSig Technologies, Inc.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: BioSig Technologies, Inc. via Globenewswire
Följ NASDAQ OMX
Skriv in din e-postadress så får du ett mejl när vi har något nytt att berätta.
Senaste nyheterna från NASDAQ OMX
Forterra Announces Definitive Agreement with Thompson Pipe Group26.6.2017 14:00 | Pressmeddelande
Thompson Pipe Group to Acquire Forterra's U.S. Concrete and Steel Pressure Pipe Assets Forterra to Acquire Thompson Pipe's Drainage Pipe & Products Manufacturing Facility with a Strategic Position in Houston Market IRVING, Texas, June 26, 2017 (GLOBE NEWSWIRE) -- Forterra, Inc. ("Forterra" or the "Company") (Nasdaq:FRTA), a leading manufacturer of water infrastructure pipe and products in the United States and Eastern Canada, today announced it has entered into a definitive agreement to sell the U.S. concrete and steel pressure pipe assets of its Water Pipe and Products business segment to Thompson Pipe Group. The transaction is subject to customary closing conditions and is expected to close in the third quarter of 2017. Under the terms of the agreement, an affiliate of Thompson Pipe Group will acquire assets related to five Forterra manufacturing facilities and a fittings facility. Forterra will receive approximate
Nasdaq Closing Cross Calculates Russell US Indexes Reconstitution for the 14th Consecutive Year24.6.2017 01:52 | Pressmeddelande
A new record $28.9 billion traded at the closing cross in a Russell reconstitution NEW YORK, June 23, 2017 (GLOBE NEWSWIRE) -- Nasdaq (Symbol: NDAQ) today announced the Nasdaq Closing Cross was used for the 14th consecutive year to rebalance Nasdaq-listed securities in the entire family of Russell US Indexes, part of leading global index provider FTSE Russell, during its annual reconstitution. More than 972 million shares representing a record $28.9 billion were executed in the Nasdaq Closing Cross in 0.861 seconds across some 2,499 Nasdaq-listed stocks. The previous record for dollars traded at the closing cross in a Russell reconstitution was $21.1 billion in 2015. "For the 14th consecutive year of partnering with FTSE Russell on the rebalance, we witnessed the advanced capabilities and market integrity of Nasdaq's INET technology platform resulting in transparent and efficient price discovery which benefits issuers and investors alike,"
LifeSci Advisors' Board Placement Initiative Announces Ninth Board Placement23.6.2017 17:52 | Pressmeddelande
NEW YORK, June 23, 2017 (GLOBE NEWSWIRE) -- LifeSci Advisors, a leading life sciences-focused investor relations consultancy, announced today the ninth placement of a female executive to a life sciences company board as part of their Board Placement Initiative (BPI), a program launched a year ago with the goal to connect female executives in the life sciences industry with companies looking for board candidates. LifeSci is pleased to share news of the appointment of Jean M. Franchi to the Board of Directors of Biophytis, a biotech company listed on Euronext Paris (ALBPS) focused on drugs that target diseases of aging, with drug candidates in clinical development for dry AMD and Sarcopenia. "I'm honored to join the Biophytis board, and look forward to helping the company achieve a more global presence as it advances its portfolio of innovative therapies addressing unmet needs associated with aging," said Ms. Franchi. "I want to extend my kind thanks to LifeSci
Fentress Architects Announces its Annual Student Global Challenge23.6.2017 09:00 | Pressmeddelande
6th edition invites students to re-envision the terminal building in the year 2075 Denver, Colorado, June 23, 2017 (GLOBE NEWSWIRE) -- Fentress Architects, based in Denver, Colorado, announces the 2017 Fentress Global Challenge, an international design competition for young and student architects. As in years past, the theme, consistent with the firm's expertise in airport design and aviation, is envisioning an airport of the future. Participants are encouraged to re-envision the terminal building in the year 2075 using one of 10 existing international airports, taking into consideration local context, technological trends, and project feasibility and passenger experience. This is the sixth year that Fentress Architects has sponsored and administered the award, which brings a First Prize of $15,000 and a summer internship at Fentress' Denver office; four additional winners will receive smaller cash awards.
Oxford Immunotec Announces National Reimbursement for the T-SPOT®.TB Test in France22.6.2017 22:50 | Pressmeddelande
OXFORD, United Kingdom and MARLBOROUGH, Mass., June 22, 2017 (GLOBE NEWSWIRE) -- Oxford Immunotec Global PLC (Nasdaq:OXFD), a global, high-growth diagnostics company focused on developing and commercializing proprietary tests for the management of underserved immune-regulated conditions, today announced a decision from the French Ministry of Health and Social Affairs to reimburse interferon gamma release assays, or IGRAs, for latent TB screening in at risk patient populations. Upon implementation of the new reimbursement codes, which is expected in the next 21 days, the French Ministry of Health and Social Affairs will provide reimbursement for the T-SPOT. TB test at a rate of approximately 60 Euros per test. About Oxford Immunotec Oxford Immunotec Global PLC is a global, high-growth diagnostics company focused on developing and commercializing proprietary tests for the management of underserved immune-r
Standard Lithium Raises $7.4 Million in Oversubscribed Financing22.6.2017 21:49 | Pressmeddelande
NOT FOR DISTRIBUTION TO UNITED STATES NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES VANCOUVER, British Columbia, June 22, 2017 (GLOBE NEWSWIRE) -- Standard Lithium Ltd. ("Standard Lithium" or the "Company") (TSXV:SLL) (FRA:S5L) is pleased to announce that it has completed the private placement of 9,894,785 common shares at a price of $0.75 per share for gross proceeds of $7,421,089. Interest in the placement far exceeded the expectations of the Company, and the additional amount raised provides the Company with the capital needed to advance its current projects and pursue strategic acquisitions in the lithium sector. "We are extremely pleased with the interest received in this placement, and completion represents a significant milestone for the Company," commented Anthony Alvaro, a director of the Company. "The strong demand speaks to the growing confidence in our team, projects and futur
I vårt nyhetsrum kan du läsa de senaste nyheterna, få tillgång till pressmaterial och hitta kontaktinformation.Besök vårt nyhetsrum